Pharmaceutical - Belgium

Filter

Current filters:

Belgium

Popular Filters

Ablynx receives $2.8 million grant to investigate nanobodies in eye disease treatment

Ablynx receives $2.8 million grant to investigate nanobodies in eye disease treatment

18-08-2014

Belgian drug developer Ablynx has received a 2.1 million euro ($2.8 million) grant from the Flemish Agency…

AblynxBelgiumOphthalmicsPharmaceuticalResearch

Belgian pharma trade body issues recommendations on domestic drug shortages

Belgian pharma trade body issues recommendations on domestic drug shortages

11-08-2014

Belgium’s pharmaceutical trade body, pharma.be, has issued a conclusion of its report on the shortage…

BelgiumMarkets & MarketingPharmaceuticalRegulation

Eisai's Fycompa launches in Belgium for partial-onset seizures

Eisai's Fycompa launches in Belgium for partial-onset seizures

04-08-2014

Fycompa (perampanel), an epilepsy drug developed by Japanese dug major Eisai, launches today in Belgium.

BelgiumCentral nervous systemEisaiEpilepsyFycompaJapanNeurologicalPharmaceuticalRegulation

UCB expands access to clinical trial data

UCB expands access to clinical trial data

01-08-2014

Belgian drugmaker UCB is now part of the Multi-Sponsor Environment, allowing for the responsible sharing…

BelgiumClinical researchPharmaceuticalResearchUCB

UCB reports solid 1st-half performance

UCB reports solid 1st-half performance

31-07-2014

Belgian drugmaker UCB posted first-half 2014 revenue of 1.76 billion euros ($2.36 billion), plus 6%,…

BelgiumChemistryChief executiveEURFinancialOrganic chemistryPharmaceuticalUCBVimpat

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

Belgium’s steps to share medical data echoed in UK

Belgium’s steps to share medical data echoed in UK

12-02-2014

Belgium’s Deputy Prime Minister Alexander De Croo has put forward the case to make available anonymized…

BelgiumHealthcarePharmaceuticalPoliticsUK

ThromboGenics founder Désiré Collen to retire

ThromboGenics founder Désiré Collen to retire

09-12-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen…

BelgiumBoardroomEuropePharmaceuticalThromboGenics

Company Spotlight

ImmunoGen

ImmunoGen

Back to top